This is a working overview of REV-ERB agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
An analytical ultracentrifuge has a light source and optical detectors. To allow the light to pass through the analyte during the ultracentrifuge run, specialized cells are required which have to meet high optical standards as well as to resist the centrifugal forces. Each cell consists of a housing, two windows made from optically pure quartz glass, and a centrepiece with one or two sectors and filling holes for the sector(s), closed with a screw plug in the housing. These cell are placed into a rotor cavity with a continuous bore, with a collar at the bottom to retain the cell. By applying specific equipment and adapting measurement parameters several types of experiments can be performed. Most common AUC experiments are sedimentation velocity and sedimentation equilibrium experiments.
Uranium (92U) is a naturally occurring radioactive element (radioelement) with no stable isotopes. It has two primordial isotopes, uranium-238 and uranium-235, that have long half-lives and are found in appreciable quantity in Earth's crust. The decay product uranium-234 is also found. Other isotopes such as uranium-233 have been produced in breeder reactors. In addition to isotopes found in nature or nuclear reactors, many isotopes with far shorter half-lives have been produced, ranging from 214U to 242U (except for 220U). The standard atomic weight of natural uranium is 238.02891(3). Natural uranium consists of three main isotopes, 238U (99.2739–99.2752% natural abundance), 235U (0.7198–0.7202%), and 234U (0.0050–0.0059%). All three isotopes are radioactive (i.e., they are radioisotopes), and the most abundant and stable is uranium-238, with a half-life of 4.463×109 years (about the age of the Earth). Uranium-238 is an alpha emitter, decaying through the 18-member uranium series into lead-206. The decay series of uranium-235 (historically called actino-uranium) has 15 members and ends in lead-207. The constant rates of decay in these series makes comparison of the ratios of parent-to-daughter elements useful in radiometric dating. Uranium-233 is made from thorium-232 by neutron bombardment.
Performance of manufactured batteries has improved over time. For example, from 1991 to 2005 the energy capacity per price of lithium-ion batteries improved more than ten-fold, from 0.3 W·h per dollar to over 3 W·h per dollar. In the period from 2011 to 2017, progress has averaged 7.5% annually. Overall, between 1991 and 2024, prices for all types of lithium-ion cells (in dollars per kWh) fell approximately 99%. From 1991 to 2018, energy density more than tripled. Efforts to increase energy density contributed significantly to cost reduction. Energy density can also be increased by improvements in the chemistry of the cell, for instance, by full or partial replacement of graphite with silicon. Silicon anodes enhanced with graphene nanotubes to eliminate the premature degradation of silicon allow for record-breaking battery energy density of up to 350 Wh/kg and lowering EV prices to be competitive with ICEs. Differently sized cells of the same format (shape) with the same chemistry may have different energy densities. Jelly roll cells usually have a higher energy density than coin or prismatic cells of the same Ah, because of a tighter/compresses packing of the cell layers. Among cylindrical cells, those with a larger size have a larger energy density, albeit the exact value strongly depends on the thickness of the electrode layers. The disadvantage of large cells is decrease of the heat transfer from the cell to its surroundings.
== References == Caldwell, Richard, Hesiod's Theogony, Focus Publishing/R. Pullins Company (1 June 1987). ISBN 978-0-941051-00-2. Clay, Jenny Strauss, Hesiod's Cosmos, Cambridge University Press, 2003. ISBN 978-0-521-82392-0. Gantz, Timothy, Early Greek Myth: A Guide to Literary and Artistic Sources, Johns Hopkins University Press, 1996, Two volumes: ISBN 978-0-8018-5360-9 (Vol. 1), ISBN 978-0-8018-5362-3 (Vol. 2). Kallich, Martin. "Oedipus and the Sphinx." Oedipus: Myth and Drama. N.p.: Western, 1968. N. pag. Print. Most, G.W., Hesiod, Theogony, Works and Days, Testimonia, Edited and translated by Glenn W. Most, Loeb Classical Library No. 57, Cambridge, Massachusetts, Harvard University Press, 2018. ISBN 978-0-674-99720-2. Online version at Harvard University Press. Stewart, Desmond. Pyramids and the Sphinx. [S.l.]: Newsweek, U.S., 72. Print. Taheri, Sadreddin (2013). "Gopat (Sphinx) and Shirdal (Gryphon) in the Ancient Middle East". نشریه هنرهای زیبا- هنرهای تجسمی. 17 (4(زمستان 1391)). Tehran: Honarhay-e Ziba Journal, Vol. 17, No. 4. doi:10.22059/jfava.2013.30063.
Sources: en.wikipedia.org
=== Articulata hypothesis === The grouping proposed by Aguinaldo et al. is almost universally accepted, replacing an older hypothesis that Panarthropoda should be classified with Annelida in a group called the Articulata, and that Ecdysozoa are polyphyletic. Nielsen has suggested that a possible solution is to regard Ecdysozoa as a sister-group of Annelida, though later considered them unrelated. Inclusion of the roundworms within the Ecdysozoa was initially contested but since 2003, a broad consensus has formed supporting the Ecdysozoa and in 2011 the Darwin–Wallace Medal was awarded to James Lake for the discovery of the New Animal Phylogeny consisting of the Ecdysozoa, the Lophotrochozoa, and the Deuterostomia.
== Reception == Half a Life was enthusiastically received by critics in America and abroad. Writing in The Guardian, writer and critic Robert McCrum called the book "a masterpiece....'Half my life ago, I killed a girl'. You'll rarely get a better first line. What follows—Strauss's precise, honest and rigorous account of a fateful road accident and its harrowing aftermath—fulfills every hope aroused in the casual reader." In the Chicago Tribune, critic Elizabeth Taylor called it "a book that inspires admiration, sentence by sentence...This is memoir in its finest form." Writer Dani Shapiro, in The New York Times Book Review, found the memoir "elegant, painful, stunningly honest." She continued, "At the center of this memoir thrums a question fundamental to what it means to be human: What do we do with what we’ve been given?" A critical favorite in the UK, Half a Life was called "one of the best books I have ever read" by Ali Catterall on the BBC, as well as "precise, elegantly written, fresh, wise, and very sad ... indicative not only of a very talented writer, but of a proper human being” by Nick Hornby Half a Life was widely excerpted in venues such as GQ, This American Life, United Kingdom papers The Times and Daily Mail.
=== Protein === Protein HtrA2, also known as Omi, is a mitochondrially-located serine protease. The human protein Serine protease HTRA2, mitochondrial is 49kDa in size and composed of 458 amino acids. The peptide fragment of 1-31 amino acid is the mitochondrial transition sequence, fragment 32-133 amino acid is propertied, and 134-458 is the mature protein Serine protease HTRA2, mitochondrial, and its theoretical pI of this protein is 6.12. HtrA2 shows similarities with DegS, a bacterial protease present in the periplasm of gram-negative bacteria. Structurally, HtrA2 is a trimeric molecule with central protease domains and a carboxy-terminal PDZ domain, which is characteristic of the HtrA family. The PDZ domain preferentially binds C-terminus of the protein substrate and modulate the proteolytic activity of the trypsin-like protease domain.
== Early life, education and career == Roy was born in the Indian state of West Bengal. He completed his schooling at Ballygunge Government High School, then obtained a first class honours degree in chemistry (BSc Hons) from Presidency College, Calcutta in 1974 and did his doctoral studies at the University of Delaware under the guidance of Prof. Roberta F. Colman to secure a PhD in 1981. His post-doctoral studies were at Brandeis University at the laboratory of Prof. Alfred Redfield (1981–82) and at the National Institutes of Health (1982–86). Returning to India in 1986, he joined Bose Institute, Kolkata as a senior lecturer in the department of biophysics. He served the Institute till 2004 holding positions of Reader and then Professor of Biophysics when he moved to the Indian Institute of Chemical Biology (IICB) as its director. After completing 10 years as the director of IICB, he returned to Bose Institute in 2014 as a senior professor and dean of studies. While at IICB, he has served the nation in several different high-level capacities such as the founder-director-in-charge of the National Institute of Pharmaceutical Education and Research, Kolkata (NIPER) (2007–14), the cluster director of 11 Biological institutes of the Council of Scientific and Industrial Research (CSIR) (2009–14), member of the governing body of the CSIR and as a visiting professor at Osaka University (2012). He has served as the president of the West Bengal Academy of Science and Technology. He is the founder-president of the Chemical Biology Society of India.
The Sudetenland ( soo-DAY-tən-land, German: [zuˈdeːtn̩ˌlant]; Czech and Slovak: Sudety) is the historical German name for the northern, southern, and western areas of former Czechoslovakia which were inhabited primarily by Sudeten Germans. These German speakers had predominated in the border districts of Bohemia, Moravia, and Czech Silesia since the Middle Ages. The word Sudetenland did not come into being until the early part of the 20th century and did not come to prominence until almost two decades into the century, after World War I, when Austria-Hungary disintegrated and the Sudeten Germans found themselves living in the new country of Czechoslovakia. The Sudeten crisis of 1938 was provoked by the Pan-Germanist demands of Nazi Germany that the Sudetenland be annexed to them, which happened after the later Munich Agreement. Part of the borderland was invaded and annexed by Poland. Afterwards, the formerly unrecognized Sudetenland became an administrative division of Germany. When Czechoslovakia was reconstituted after World War II, the Sudeten Germans were expelled and the region today is inhabited almost exclusively by Czech speakers. The word Sudetenland is a German compound of Sudeten, the name of the Sudeten Mountains, which run along the northern Czech border and Lower Silesia (now in Poland), and Land, meaning "country". The Sudetenland encompassed areas well beyond those mountains, however. Parts of the now-Czech regions of Karlovy Vary, Liberec, Olomouc, Moravia-Silesia, South Moravia and Ústí nad Labem are within the former Sudetenland.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.